Bibliography
- Kessler RC, Merikangas KR, Wang PS. Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu Rev Clin Psychol 2007;3:137-58
- Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res 2003;12:22-33
- Kessler RC, Akiskal HS, Ames M, Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry 2006;163:1561-8
- Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 2006;27:2763-74
- Hartzell JD, Janke IE, Weintrob AC. Impact of depression on HIV outcomes in the HAART era. J Antimicrob Chemother 2008;62:246-55
- Benton T, Staab J, Evans DL. Medical co-morbidity in depressive disorders. Ann Clin Psychiatry 2007;19:289-303
- Rush AJ, Trivedi MH, Wisniewski SR, Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
- Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649-59
- Cipriani A, La Ferla T, Furukawa TA, Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev 2010;CD006117
- Bauer M, Tharmanathan P, Volz H-P, The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 2009;259:172-85
- Cipriani A, Santilli C, Furukawa TA, Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009;CD006532
- Watanabe N, Omori IM, Nakagawa A, Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. J Clin Psychiatry 2008;69:1404-15
- Montgomery SA, Baldwin DS, Blier P, Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007;22:323-9
- Anderson IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 1998;7(Suppl 1):11-17
- Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58(1):19-36
- Cipriani A, Furukawa TA, Salanti G, Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58
- Deshauer D, Moher D, Fergusson D, Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials. CMAJ 2008;178:1293-301
- Hunot VM, Horne R, Leese MN, Churchill RC. A cohort study of adherence to antidepressants in primary care: the influence of antidepressant concerns and treatment preferences. Prim Care Companion J Clin Psychiatry 2007;91-9
- Thase ME, Haight BR, Richard N, Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005;66:974-81
- Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol (Oxford) 2008;22:843-8
- Papakostas GI. The efficacy, tolerability, and safety of contemporary antidepressants. J Clin Psychiatry 2010;71(Suppl E1):e03
- Marcus SC, Olfson M. National trends in the treatment for depression from 1998 to 2007. Arch Gen Psychiatry 2010;67:1265-73
- Cipriani A, Barbui C, Butler R, Depression in adults: drug and physical treatments. Clin Evid (Online) 2011;2011:1003
- Deecher DC, Beyer CE, Johnston G, Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318:657-65
- Pfizer, Inc. Manufacturers Package insert for Pristiq®
- Thase ME, Kornstein SG, Germain JM, An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr 2009;14:144-54
- Liebowitz MR, Manley AL, Padmanabhan SK, Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008;24:1877-90
- Boyer P, Montgomery S, Lepola U, Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008;23(5):243-53
- Tourian KA, Padmanabhan SK, Groark J, Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 2009;31(Pt 1):1405-23
- Clayton AH, Kornstein SG, Rosas G, An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr 2009;14:183-95
- Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 2009;14:536-46
- Sheehan DV, Croft HA, Gossen ER, Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry (Edgmont) 2009;6:20-33
- Rickels K, Athanasiou M, Robinson DS, Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:326-33
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00683592
- Khan A, Cutler AJ, Kajdasz DK, A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry 2011;72(4):441-7
- Portella MJ, de Diego-Adelino J, Ballesteros J, Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry 2011;72:962-9
- Papakostas GI, Shelton RC, Smith J, Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 2007;68:826-31
- Shelton RC, Tollefson GD, Tohen M, A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4
- Shelton RC, Williamson DJ, Corya SA, Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005;66:1289-97
- Corya SA, Williamson D, Sanger TM, A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006;23:364-72
- Thase ME, Corya SA, Osuntokun O, A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007;68:224-36
- Berman RM, Marcus RN, Swanink R, The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:843-53
- Marcus RN, McQuade RD, Carson WH, The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:156-65
- Berman RM, Fava M, Thase ME, Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009;14:197-206
- Bauer M, Pretorius HW, Constant EL, Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009;70:540-9
- El-Khalili N, Joyce M, Atkinson S, Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010;13:917-32
- Jayanthi LD, Ramamoorthy S. Regulation of monoamine transporters: influence of psychostimulants and therapeutic antidepressants. AAPS J 2005;7:E728-38
- Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: the next generation of antidepressants. Curr Neuropharmacol 2008;6:338-43
- Srinivasan V, Singh J, Pandi-Perumal SR, Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs. Adv Ther 2010;27:796-813
- Branchey L, Weinberg U, Branchey M, Simultaneous study of 24-hour patterns of melatonin and cortisol secretion in depressed patients. Neuropsychobiology 1982;8:225-32
- Claustrat B, Chazot G, Brun J, A chronobiological study of melatonin and cortisol secretion in depressed subjects: plasma melatonin, a biochemical marker in major depression. Biol Psychiatry 1984;19:1215-28
- Nair NP, Hariharasubramanian N, Pilapil C. Circadian rhythm of plasma melatonin in endogenous depression. Prog Neuropsychopharmacol Biol Psychiatry 1984;8:715-18
- Beck-Friis J, Kjellman BF, Aperia B, Serum melatonin in relation to clinical variables in patients with major depressive disorder and a hypothesis of a low melatonin syndrome. Acta Psychiatr Scand 1985;71:319-30
- Sekula LK, Lucke JF, Heist EK, Neuroendocrine aspects of primary endogenous depression. XV: mathematical modeling of nocturnal melatonin secretion in major depressives and normal controls. Psychiatry Res 1997;69:143-53
- Crasson M, Kjiri S, Colin A, Serum melatonin and urinary 6-sulfatoxymelatonin in major depression. Psychoneuroendocrinology 2004;29(1):12
- Naranjo CA, Tremblay LK, Busto UE. The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:781-823
- Stahl SM, Fava M, Trivedi MH, Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 2010;71:616-26
- San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 2008;23:396-402
- Zajecka J, Schatzberg A, Stahl S, Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2010;30:135-44
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00705003
- Bielski RJ, Cunningham L, Horrigan JP, Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. J Clin Psychiatry 2008;69:571-7
- Adell A. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety. IDrugs 2010;13:900-10
- Thompson AJ, Lummis SC. The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets 2007;11:527-40
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00672620
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00635219
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00735709
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00672958
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT01140903
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT01255787
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT01163266
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT01153009
- Vaishnavi SN, Nemeroff CB, Plott SJ, Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004;55:320-2
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00969150
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00969709
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT01085812
- Dube S, Dellva MA, Jones M, A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. J Psychiatr Res 2010;44:356-63
- Pangallo B, Dellva MA, D'Souza DN, A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder. J Psychiatr Res 2011;45(6):748-55
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT01155661
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT01185340
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT01173601
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT01187407
- Anon. Lundbeck and Takeda finalise plans to initiate phase III pivotal clinical trials with Lu AA21004 and Lu AA24530 (March 3, 2010) | 2010 | Newsroom | Takeda Pharmaceutical Co. Ltd. Available from: http://www.takeda.com/press/article_35859.html [Accessed 21 November 2010]
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00599911
- Press release, Lundbeck & Takeda, 3 Mar 2010; Co. pipeline, Takeda, 30 Jul 2010. Available from: http://www.takeda.com/pdf/usr/default/11_1_37769_2.pdf
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00896363
- Wade AG, Crawford GM, Nemeroff CB, Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response. Psychol Med 2011;41(10):2089-97
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00854100
- Available from: http://www.otsuka.com/en/rd/pharmaceuticals/pipeline/pdf.php?financial=27, retrieved 4/4/2011
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00797966
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT01052077
- Tran P, Skolnick P, Czobor P, Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res 2012; 46(1):64-71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21925682. [ [Accessed 21 November 2011]
- Available from: http://www.euthymics.com/pdf/2010.07.22%20Press%20Release%20-%20Euthymics%20Series%20A.pdf [Retrieved 4 April 2011]
- Fowler JS, Logan J, Azzaro AJ, Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology 2010;35:623-31
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00739908
- Available from: http://www.cenerx.com/News/releases/1-JAN-11.pdf Retrieved 4 April [2011]
- Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology 2009;57:608-18
- Candy M, Jones L, Williams R, Psychostimulants for depression. Cochrane Database Syst Rev 2008(2):CD006722
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00905424
- http://www.rexahn.com/cms/index.php/2010/04/rexahn-pharmaceuticals-announces-Phase-iia-study-results-of-serdaxin-in-major-depressive-disorder-mdd/ retrieved 4/4/2011
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT01273376
- Graef S, Schonknecht P, Sabri O, Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings. Psychopharmacology (Berl) 2011;215:205-29
- Breslau N. Psychiatric comorbidity of smoking and nicotine dependence. Behav Genet 1995;25:95-101
- Glassman AH, Helzer JE, Covey LS, Smoking, smoking cessation, and major depression. JAMA 1990;264:1546-9
- Mineur YS, Picciotto MR. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 2010;31:580-6
- Rabenstein RL, Caldarone BJ, Picciotto MR. The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology (Berl) 2006;189:395-401
- Reitstetter R, Lukas RJ, Gruener R. Dependence of nicotinic acetylcholine receptor recovery from desensitization on the duration of agonist exposure. J Pharmacol Exp Ther 1999;289:656-60
- Press releases, Targacept, 21 Jul 2008 & 12 Feb & 15 Jul & 15 Oct 2009; 3rd Qtr Res, Targacept, 2008; Form 10-K, Targacept, 2008, retrieved 4/4/2011
- Available from: http://www.astrazeneca.com/media/latest-press-releases/TC-5214_initiates_Phase_3_trial?itemId=9730422 [Retrieved 4 April 2011]
- Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006;63:1121-9
- Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 2010;67:432-8
- Available from: http://www.braincellsinc.com/wp-content/uploads/2010/08/BCI-PR-08042010.pdf [Retrieved 20 February 2011]
- Shors TJ, Foy MR, Levine S, Unpredictable and uncontrollable stress impairs neuronal plasticity in the rat hippocampus. Brain Res Bull 1990;24:663-7
- Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990;185:1-10
- Berman RM, Cappiello A, Anand A, Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-4
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00491686
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00781742
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00986479
- Zarate C Jr, Machado-Vieira R, Henter I,, Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry 2010;18:293-303
- Bessho Y, Nakanishi S, Nawa H. Glutamate receptor agonists enhance the expression of BDNF mRNA in cultured cerebellar granule cells. Brain Res Mol Brain Res 1993;18:201-8
- Yuzaki M, Furuichi T, Mikoshiba K, A stimulus paradigm inducing long-term desensitization of AMPA receptors evokes a specific increase in BDNF mRNA in cerebellar slices. Learn Mem 1994;1:230-42
- Lauterborn JC, Lynch G, Vanderklish P, Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci 2000;20:8-21
- Krishnan V, Nestler EJ. Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 2010;167:1305-20
- Frizzo ME, Dall'Onder LP, Dalcin KB, Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol 2004;24:123-8
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00621270
- Available from: http://www.braincellsinc.com/wp-content/uploads/2010/06/BCI-PR-06142010.pdf Retrieved 25 February 2011 ]
- Krystal JH, Mathew SJ, D'Souza DC, Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 2010;24:669-93
- Romano C, Sesma MA, McDonald CT, Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 1995;355:455-69
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT01145755
- Jutkiewicz EM. The antidepressant -like effects of delta-opioid receptor agonists. Mol Interv 2006;6:162-9
- Broom DC, Jutkiewicz EM, Rice KC, Behavioral effects of delta-opioid receptor agonists: potential antidepressants? Jpn J Pharmacol 2002;90(1):6
- Jutkiewicz EM, Rice KC, Woods JH, Effects of the delta-opioid receptor agonist SNC80 on learning relative to its antidepressant-like effects in rats. Behav Pharmacol 2003;14:509-16
- Perrine SA, Hoshaw BA, Unterwald EM. Delta opioid receptor ligands modulate anxiety-like behaviors in the rat. Br J Pharmacol 2006;147:864-72
- Saitoh A, Kimura Y, Suzuki T, Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J Pharmacol Sci 2004;95:374-80
- Hirose N, Murakawa K, Takada K, Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens. Neuroscience 2005;135:213-25
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT01020799
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00759395
- Gundlach AL, Largent BL, Snyder SH. Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. J Neurosci 1986;6:1757-70
- Fishback JA, Robson MJ, Xu YT, Sigma receptors: potential targets for a new class of antidepressant drug. Pharmacol Ther 2010;127:271-82
- Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996;307:117-19
- Su TP, London ED, Jaffe JH. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 1988;240:219-21
- Su TP, Shukla K, Gund T. Steroid binding at sigma receptors: CNS and immunological implications. Ciba found Symp 1990;153:107-13. discussion 113-6
- Maurice T. Neurosteroids and sigma1 receptors, biochemical and behavioral relevance. Pharmacopsychiatry 2004;37(Suppl 3):S 171-82
- Akunne HC, Zoski KT, Whetzel SZ, Neuropharmacological profile of a selective sigma ligand, igmesine: a potential antidepressant. Neuropharmacology 2001;41:138-49
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00551109
- Available from: http://www.m-sci.com/e/kaihatsu/pipeline.html [Retrieved 1 April 2011]
- Mantyh PW. Neurobiology of substance P and the NK1 receptor. J Clin Psychiatry 2002;63(Suppl 11):6-10
- Morcuende S, Gadd CA, Peters M, Increased neurogenesis and brain-derived neurotrophic factor in neurokinin-1 receptor gene knockout mice. Eur J Neurosci 2003;18:1828-36
- Park SW, Yan YP, Satriotomo I, Substance P is a promoter of adult neural progenitor cell proliferation under normal and ischemic conditions. J Neurosurg 2007;107:593-9
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00880399
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00880048
- Nemeroff CB. Early-life adversity, CRF dysregulation, and vulnerability to mood and anxiety disorders. Psychopharmacol Bull 2004;38(Suppl 1):14-20
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00733980
- http://phx.corporate-ir.net/phoenix.zhtml?c=68817&p=irol-newsArticle&ID=1471129&highlight=) [Retrieved 26 February 2011]
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT01034995
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00510822
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00976560
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT00569062
- ClinicalTrials.gov, retrieved 3/28/2011 Available from: http://clinicaltrials.gov/ct2/show/NCT01114698